ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital ...
Q1 2026 Management View Michael Farrell, CEO & Chairman, highlighted a strong quarter, reporting "9% reported revenue growth or 8% on a constant currency basis, with multiple areas of high performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback